BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 19595257)

  • 1. [rh-endostatin in combination with docetaxel and carboplatin as adjuvant treatment for non-small lung cancer].
    Qi DL; Yang YZ; Liu ZJ; Wang QS; Xin L; Cui Y; Qiao YF; Feng K
    Zhonghua Yi Xue Za Zhi; 2009 Apr; 89(15):1057-9. PubMed ID: 19595257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy of endostar combined with chemotherapy in multi-cycle treatment of patients with advanced non-small cell lung cancer].
    Li N; Jin ZL; Liu ZJ; Wang J; Li K
    Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):937-42. PubMed ID: 22340106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating endothelial cells in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Kawaishi M; Fujiwara Y; Fukui T; Kato T; Yamada K; Ohe Y; Kunitoh H; Sekine I; Yamamoto N; Nokihara H; Watabe T; Shimoda Y; Arao T; Nishio K; Tamura T; Koizumi F
    J Thorac Oncol; 2009 Feb; 4(2):208-13. PubMed ID: 19179898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy and adverse effets of nimotuzumab plus palitaxel liposome and carboplatin in the treatment for advanced non-small cell lung cancer].
    Qi DL; Wang HQ; Li Y; Huang CB; Wang QS; Xu L; Yang YZ; Cui Y; Xin L
    Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):152-5. PubMed ID: 22780937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of combination chemotherapy with docetaxel and carboplatin for elderly patients with advanced non-small cell lung cancer.
    Kim HJ; Kim TG; Lee HJ; Kim JH; Lim BH; Seo JW; Kang EM; Lee BU; Ahn YM; Roh YH; Nam SH; Kim BS
    Lung Cancer; 2010 May; 68(2):248-52. PubMed ID: 19647333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016.
    Ikeda S; Kato T; Ogura T; Sekine A; Oda T; Masuda N; Igawa S; Katono K; Otani S; Yamada K; Saito H; Kondo T; Hosomi Y; Nakahara Y; Nishikawa M; Utumi K; Misumi Y; Yamanaka T; Sakamaki K; Okamoto H
    BMC Cancer; 2018 Mar; 18(1):241. PubMed ID: 29499653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of docetaxel and carboplatin in Thai patients with advanced non-small-cell lung cancer.
    Thongprasert S; Soorraritchingchai S; Chewaskulyong B; Charoentum C; Munprakan S
    J Med Assoc Thai; 2006 Feb; 89(2):152-9. PubMed ID: 16579000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can determination of circulating endothelial cells and serum caspase-cleaved CK18 predict for response and survival in patients with advanced non-small-cell lung cancer receiving endostatin and paclitaxel-carboplatin chemotherapy? a retrospective study.
    Chu TQ; Ding H; Garfield DH; Gu AQ; Pei J; Du WD; Han BH
    J Thorac Oncol; 2012 Dec; 7(12):1781-1789. PubMed ID: 23154549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.
    Strauss GM; Herndon JE; Maddaus MA; Johnstone DW; Johnson EA; Harpole DH; Gillenwater HH; Watson DM; Sugarbaker DJ; Schilsky RL; Vokes EE; Green MR
    J Clin Oncol; 2008 Nov; 26(31):5043-51. PubMed ID: 18809614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of carboplatin combined with biweekly docetaxel for advanced non-small cell lung cancer.
    Ishimoto O; Sugawara S; Inoue A; Ishida T; Munakata M; Koinumaru S; Hasegawa Y; Suzuki T; Miki H; Saijo Y; Nukiwa T
    J Thorac Oncol; 2006 Nov; 1(9):979-83. PubMed ID: 17409982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors for the efficacy of Endostar combined with neoadjuvant chemotherapy for stage IIIA (N2) NSCLC.
    Zhao X; Wen X; Wei W; Su Y; You J; Gong L; Zhang Z; Wang M; Xiao J; Wei X; Wang C
    Cancer Biomark; 2017 Dec; 21(1):169-177. PubMed ID: 29036790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of concurrent chemoradiation with weekly docetaxel, carboplatin, and radiation therapy followed by consolidation chemotherapy with docetaxel and carboplatin for locally advanced inoperable non-small cell lung cancer (NSCLC).
    Jain AK; Hughes RS; Sandler AB; Dowlati A; Schwartzberg LS; Dobbs T; Schlabach L; Wu J; Muldowney NJ; Choy H
    J Thorac Oncol; 2009 Jun; 4(6):722-7. PubMed ID: 19404213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Circulating endothelial cells in the peripheral blood of advanced NSCLC patients].
    Huang C; Li K; Wei XY; Niu RF; Sun Y; Wang JW; Zhu YZ; Xu LY; Liu XQ; Gao HJ; Zhou JM; Wang XW
    Zhonghua Zhong Liu Za Zhi; 2006 Oct; 28(10):780-3. PubMed ID: 17366796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of docetaxel and carboplatin as second-line treatment in NSCLC.
    Wachters FM; van Putten JW; Boezen HM; Groen HJ
    Lung Cancer; 2004 Aug; 45(2):255-62. PubMed ID: 15246198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter, randomized, phase 2 study of zoledronic acid in combination with docetaxel and carboplatin in patients with unresectable stage IIIB or stage IV non-small cell lung cancer.
    Pandya KJ; Gajra A; Warsi GM; Argonza-Aviles E; Ericson SG; Wozniak AJ
    Lung Cancer; 2010 Mar; 67(3):330-8. PubMed ID: 19493585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A clinical trial on docetaxel and carboplatin therapy with or without nimotuzumab for the treatment of advanced nonsmall cell lung cancer.
    Qi D; Cui Y; Wang Q; Huang C; Xu J; Yang Y; Xin L; Tian Y; Qi XA
    J Cancer Res Ther; 2015 Aug; 11 Suppl 1():C32-7. PubMed ID: 26323921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant carboplatin-based chemotherapy in resected stage IIIA-N2 non-small cell lung cancer.
    Ou W; Sun HB; Ye X; Zhang BB; Yang H; Fang Q; Li P; Wang SY
    J Thorac Oncol; 2010 Jul; 5(7):1033-41. PubMed ID: 20502361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Analysis of cavitation of advanced NSCLC treated by rh-endostatin combined with NP chemotherapy].
    Huang C; Wang LC; Xiao JY; Ye ZX; Liu ZJ; Xu WJ; Cheng X; Wang J; Li K
    Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):712-5. PubMed ID: 19173919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequence effect of docetaxel and carboplatin on toxicity, tumor response and pharmacokinetics in non-small-cell lung cancer patients: a phase I study of two sequences.
    Ando M; Saka H; Ando Y; Minami H; Kuzuya T; Yamamoto M; Watanabe A; Sakai S; Shimokata K; Hasegawa Y
    Cancer Chemother Pharmacol; 2005 Jun; 55(6):552-8. PubMed ID: 15856233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The feasibility of adjuvant carboplatin and docetaxel in patients with curatively resected locally advanced non-small cell lung cancer.
    Sun HB; Wang SY; Ou W; Zhang BB; Yang H; Fang Q
    Lung Cancer; 2010 Jun; 68(3):403-8. PubMed ID: 19913325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.